Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis is that application of Mupirocin to the nose before and after coronary artery bypass grafting surgery will reduce the incidence of surgical site infections.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Horizon Health Network
• Treatments: Mupirocin

Criteria

Inclusion Criteria:

• Adults >18 years old undergoing Coronary Artery Bypass Grafting Surgery (CABG) with or without concomitant cardiac valve surgery or other cardiac surgery,

• Median sternotomy wound

• Capable of informed consent

Exclusion Criteria:

• Allergy to mupirocin or components

• Pregnant or lactating females

• Emergency surgery

• Pre-existing ongoing infection